

The University of Michigan Regents Communication

Request for Action

Subject: Regental Action Required Under the State of Michigan Conflict of Interest Statute

Action Requested: Authorize Execution of Investment Agreements for the Michigan Biomedical Venture Fund for AngioInsight, Inc.

Preamble:

In April 2016, the Board of Regents approved the Michigan Biomedical Venture Fund (“MBVF”) and its guidelines. The purpose of the Michigan Biomedical Venture Fund is to provide seed and pre-seed capital to biomedical start-up companies based on underlying technologies from the University of Michigan’s College of Engineering and Medical School.

The proposed investment agreements (the “Agreements”) fall under the State of Michigan Conflict of Interest Statute because the listed Interested Individuals are both employees of the University of Michigan (“University”) and partial owners of AngioInsight, Inc. (the “Company”). The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background

The Michigan Biomedical Venture Fund is seeking approval for financing agreements up to a total of no more than 10% of the fund’s total assets under management (through one or more rounds of financing) under MBVF for the below-listed startup. It is understood that, upon approval of this item, MBVF will have no obligation to enter into the Agreements or proceed with any investment in the company.

The Company, founded in 2018, develops software for the automated assessment of cardiology images.

Interested Individual(s):

Brahmajee Nallamothu, M.D., is a Professor of Internal Medicine-Cardiovascular Medicine in the University of Michigan Medical School.

C. Alberto Figueroa, Ph.D., is a Professor of Biomedical Engineering and Vascular Surgery in the University of Michigan College of Engineering and Medical School.

Pecuniary Interest:

The pecuniary interests of Brahmajee Nallamothu and C. Alberto Figueroa arise from their relationship with the Company.

Parties to the Agreement:

The Regents of University of Michigan and AngioInsight, Inc.

Agreement Terms Include:

The Michigan Biomedical Venture Fund will execute applicable standard agreements for venture capital investing. The University will receive future equity in the Company, along with the right to purchase more equity.

No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Recommendations:

We believe state law requirements have been met with the disclosure of the pecuniary interest and formal appointment arrangements with the University of Michigan. Requirements, if any, that may be applicable by the supervisors or designated conflict managers under the Conflict of Interest Policy at the applicable school, college or administrative unit within the University must be analyzed and managed in addition to the foregoing approval process.

I recommend that the Board of Regents authorize execution of agreements between the University of Michigan and AngioInsight, Inc. as set forth above.

Respectfully submitted:



David C. Miller

Executive Vice President for Medical Affairs & CEO, Michigan Medicine

September 2026